HPV16-E711-20 epitope is a well-known HLA-A*0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine.
HPV16-E711-20 epitope is a synthetic peptide derived from the E7 protein of Human Papillomavirus type 16, a high-risk HPV subtype extensively studied in the context of viral oncogenesis and immunological research. This peptide represents a well-characterized sequence commonly used as a model antigen for investigating T cell responses, antigen processing, and immune recognition related to HPV-associated malignancies. Its defined amino acid sequence and immunodominant properties make it a valuable tool for dissecting cellular mechanisms underlying viral persistence, immune evasion, and the development of virus-driven cancers in preclinical and translational research settings.
Immunological assay development: As a prototypical T cell epitope, the HPV16-E711-20 peptide is widely utilized in the development and validation of immunological assays, such as ELISpot, intracellular cytokine staining, and tetramer-based flow cytometry. These assays enable precise quantification and characterization of antigen-specific CD8+ cytotoxic T lymphocyte responses in experimental models and ex vivo human samples. By providing a consistent and well-defined target, the peptide supports standardized assessment of immune reactivity, facilitating comparative studies and method optimization across laboratories.
Cellular immunity studies: The E7-derived epitope is instrumental in exploring the mechanisms of antigen processing, presentation, and T cell activation within the context of HPV infection. Researchers employ this peptide to stimulate peripheral blood mononuclear cells or established T cell lines, allowing for detailed analysis of MHC class I-restricted recognition, effector function, and memory formation. These investigations yield insights into the immunodominance hierarchy, cross-presentation pathways, and the influence of viral antigens on host immune surveillance.
Vaccine research and evaluation: The HPV16-E711-20 peptide serves as a benchmark antigen in preclinical vaccine studies aimed at eliciting robust cellular immune responses against HPV-driven tumors. Its inclusion in peptide pools or as a single epitope enables assessment of vaccine-induced CD8+ T cell activity, supporting the optimization of vaccine formulations and adjuvant combinations. The peptide's relevance to HPV16-associated malignancies makes it a critical component in evaluating the immunogenicity and efficacy of novel immunoprophylactic and immunotherapeutic strategies in animal models and in vitro systems.
Epitope mapping and antigen discovery: Researchers leverage the defined sequence of this epitope to delineate T cell receptor specificity, map fine epitope regions within the E7 protein, and identify cross-reactive determinants among HPV variants. Such studies contribute to a deeper understanding of antigenic structure-function relationships, inform the design of next-generation peptide vaccines, and support the identification of novel targets for immunotherapy. The peptide's use in high-throughput screening platforms accelerates the discovery of immunologically relevant epitopes and the characterization of their interaction with HLA molecules.
Adoptive cell therapy research: The HPV16-E711-20 peptide is frequently employed to expand and functionally characterize HPV-specific T cell populations for adoptive transfer protocols in experimental models. By providing a defined stimulus for in vitro priming and expansion, the peptide enables selection and quality control of antigen-specific T cells, which are subsequently evaluated for cytotoxicity, persistence, and anti-tumor activity. These applications support the advancement of adoptive immunotherapy approaches targeting virally induced neoplasms, contributing to the broader field of personalized cancer immunotherapy research.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More